cyrilzakka/clinical-trials huggingface dataset:
Effect of Antigravity Treadmill in Knee Osteoarthritis (AGTreadmill)

To date, the anti-gravity treadmill, as a representative method of lower body positive pressure treadmills, has been rarely reported for knee osteoarthritis rehabilitation.

Purpose: This study aims to evaluate the effect of antigravity treadmill training on pain, gait characteristics, and function in patients with knee osteoarthritis.

The study included 40 patients with knee osteoarthritis who were randomly assigned to one of two groups: the antigravity treadmill group (n=20) or the control group (n=20 ). For 12 weeks, the antigravity treadmill group received training on the Alter G treadmill (75% weight-bearing, 30 minutes per session, three times per week) combined with traditional physical therapy. During the same period, the control group received only traditional physical therapy. The Visual Analogue Scale, Walkway System, and the Western Ontario and McMaster Universities Arthritis Index were used to assess pain, spatiotemporal gait parameters, and patient function, respectively. All outcome measures were obtained pretreatment, post-treatment, and 3 months follow-up assessment.

Eligibility Criteria:
Inclusion Criteria:

* Patients should: (1) be ≥50 years old
* Patients have been diagnosed with mild to moderate osteoarthritis by a physician and confirmed by radiograph imaging (Kellgren \& Lawrence grade 1-3)
* Patients complain of knee pain during the past 30 days when walking, squatting, and/or kneeling (the minimum level 3/10 on visual analogue scale before inclusion)
* Patients' body mass index greater than 30.

Exclusion criteria

* Patients were excluded if they have a history of ankle, knee, or hip injury or medical operation
* Have used knee injection for their knee osteoarthritis pain within the past year
* Have a history of other medical conditions that would interfere with walking
* Received physical therapy during the past 3 months for knee osteoarthritis
* Had any metabolic, pulmonary, neuromuscular, neurological, and/or autoimmune disease.
Music Therapy on Nausea and Pain for Autologous Stem Cell

Autologous stem cell transplant (ASCT) is an important therapy for patients with multiple myeloma, non-Hodgkin's lymphoma, and Hodgkin's lymphoma. It has been shown to improve progression free survival and overall survival. However, it is a challenging treatment process both physically and psychologically. It is a procedure with many side effects that can be uncomfortable, painful, and at times, difficult to endure. Complementary therapies, such as music therapy, have potential to be an important adjunct in palliation of symptoms in patients undergoing chemotherapy.

Patients randomized to receive music therapy will receive 2 sessions of live music therapy, at least 48 hours apart, from a Music Therapist-Board Certified (MT-BC, certified through the Certification Board for Music Therapists) in their room. This will occur between days -1 and +5, with the first music therapy session being as close to day +1 as possible and the second session being at least 48 hours later (but no more than 96 hours later).

Those patients randomized to standard therapy (no music therapy) are allowed to listen to music; however they will not receive interactive music therapy from a certified therapist. Following day +7, music therapy will be offered to all patients who are interested in participating.

No narcotic or anti-emetic therapy will be administered for at least 2 hours prior to music therapy sessions or to assessments. Patients will rate nausea and pain at the beginning and end of the first music therapy session on a validated visual analog scale.12-14 The scale will be 10cm with the least nausea or pain at point 0 and the greatest nausea or pain at point 10. Patients will be asked to rate their nausea and pain on day +5 and day +7.

Eligibility Criteria:
Inclusion Criteria:

* Be older than 18 years of age
* Have a diagnosis of multiple myeloma, non-Hodgkin, or Hodgkin lymphoma
* Be undergoing ASCT (Autologous Stem Cell Transplantation)

Exclusion Criteria:

* Have had previous ASCT
* Have a diagnosis of leukemia
* History of prior music therapy
Evaluation of the CR Plug (Allograft) for the Treatment of a Cartilage Injury in the Knee.

Determine the ability of the allograft plug for the treatment of a cartilage injury in the knee

The specific aim in this study is to assess the ability of the CR-Plug to treat osteochondral focal defects of less than 2.5 cm squared at high-load-bearing femoral condyle.

Eligibility Criteria:
Inclusion Criteria:

* 18 years of age or older
* Skeletally mature
* Have one symptomatic score International Cartilage Repair Score (ICRS) grade 3a, 3b, 3c, 3d, 4a, 4b articular cartilage lesion less than 2.5 cm involving the Medial Femoral Condyle (MFC) or Lateral Femoral Condyle (LFC). Symptoms must include pain, pain with weight bearing and squatting, locking of joints, and/or swelling
* Functional meniscal tissue (defined as 5 mm or more width)
* A score of = or greater than 4 on the VAS questionnaire

Exclusion Criteria:

* Associated tibial or patellar articular cartilage defect greater than 2 ICRS
* Osteoarthritis of either knee
* Mechanical axis malalignment of greater than 5 degrees
* Patellofemoral incongruity of Merchant view
* One or more multiple defects greater than 2.5 cm
* Osteochondritis dissecans (OCD) with depth of bone loss greater than 4 mm
* Ligament treatments in the affected knee within one yer prior to current study
* Previous surgical meniscus treatments in the affected knee in the last 6 months
* Less than 5 mm of meniscal tissue in ipsilateral compartment of study treatment
* Use of any investigational therapy with in 30 days prior to the first visit
* Corticosteroid or viscosupplementation within the past 3 months
* A score of 3 or less on the VAS Questionnaire
* Active gout or pseudogout or systemic inflammatory condition
Infiltration Effect on SUV

A widely used semi-quantitative parameter to assess tumor status is the standardized uptake value (SUV). SUV estimation accuracy can be impacted by many variables. Today there still exists a significant amount of variability in PET/CT results in test and re-test studies. This variability can be introduced by instrumentation and subject-specific factors. Variability reduces image quality and increases the required changes in tumor quantification to reflect real tumor response or progression.

PET/CT scanning process requires that the entire net injected dose of radiolabeled tracer is administered intravenously as a bolus. The quality and quantification of a PET/CT image is highly dependent on the uptake of radiolabeled tracer. Boellaard et al. have indicated infiltrations could potentially underestimate SUV measurements by as much as 50%. Infiltrations and obstructions are not uncommon.

Recent studies using a novel QA/QC tool (LaraTM System) for the radiotracer injection process revealed that current means to detect infiltration do not completely identify all infiltrations/obstructions. Since infiltrations may not be visible in the standard field of view (FOV) and since the impact of a peripheral circulatory obstruction may not be visible even if an injection site is in the FOV, it is possible for reading and treating physicians to be unaware that a patient's image and quantification has been impacted. Additionally, when current means do detect an infiltration, they under-represent the severity because they are not capturing that infiltrations often resolve during the uptake period. As a result, infiltrations or obstructions may cause SUV inaccuracy and could adversely impact staging and tumor assessments.

The purpose of this study will be to characterize the impact of moderate or greater infiltrations on standardized uptake values. Patients experiencing a moderate or greater infiltration on a routine clinical PET scan will be invited to return for a repeat scan with injection performed by specially trained personnel to reduce the risk of repeat infiltration. The two scans will be compared to assess for changes in tumor uptake intensity.


Eligibility Criteria:
Inclusion Criteria:

* Subjects with solid tumors undergoing PET/CT scan who have at least one measurable target lesion and sustain a moderate or greater infiltration.

Exclusion Criteria:

* Subjects unwilling or unable to tolerate a repeat PET/CT scan.
* Subjects with meaningful medical intervention between PET/CT scans that would likely impact SUV.
* Subjects with follow up injection infiltrations that would likely impact the SUV.
* Pregnant patients.
Eustachian Tube Dysfunction Assessment

The purpose of the study is to understand the exact mechanism of the activity of paratubal muscles in opening eustachian tube in patients with the functional eustachian tube and those with the eustachian tube dysfunction problem.

In this study adult patients with normal and abnormal middle ears with documented tympanogram were tested to detect the Levator Veli Palatini (mLVP) and the tensor Veli Palatini (mTVP) electromyographic (EMG) activities corresponding to eustachian tube (ET) opening at rest. The subjects were mixed some with and some without ET dysfunction (ETD). Tests were conducted at an audiology unit at a tertiary care center located near at sea level, constant atmospheric pressure and temperature. Subjects are to be selected randomly with and without eustachian tube dysfunction (ETD) by using a questionnaire and evaluated with tympanometry and tympanic air exchange testing of the external ear canal for testing the ET openings. Monopolar and reference needle electrodes for each muscle were inserted transpalatally on the test side without topical anesthetics. Tympanic air exchange test is done by placing a pressure sensor into the external ear canal of the patient as well as a nasal pressure sensor for detecting ET openings during EMG recording. Information received from ear pressure and nasal pressure sensor of tympanic air exchange sensor (TAS) equipment was used for assessing the swallowing efficacy of the healthy subjects. Simultaneous correspondent recordings of the ET openings during the test as well as the electromyographic activity for the mLVP, mTVP were recorded.

Eligibility Criteria:
Inclusion criteria:

* Patients are selected from outpatients visiting Department of Otolaryngology of Haseki Hospital with a mixture of healthy Eustachian tube and with Eustachian Tube Dysfunction problem who agreed to participate in the study after being informed and signed the consent form. Questionnaire (ETDQ-7) is used for initial determination of those with and without ET dysfunction problem to include the sufficient number of patients with ETD problem in the batch.

Exclusion criteria:

* All of the subjects had an examination of the tympanic membrane, middle ear, nasal cavity and nasopharynx.
* Patients with severe septal deformities, nasal polyps and turbinate hypertrophy, adenoid and other nasopharyngeal masses were excluded.
* Patients with upper respiratory tract infections, acute otitis media, tympanosclerosis, otosclerosis and those who had previous ear surgery were not included in the study group.
Evaluation of a New Ultrasound System for the Non-invasive Assessment of Liver Steatosis in MASLD/MASH Patients

The objective of the study is to evaluate a new ultraportable ultrasound device, Hepatoscope, for the non-invasive assessment of hepatic steatosis in patients presenting with steatopathy from metabolic origin, by comparing its measurements with current diagnostic modalities, such as MRI PDFF.

The objective of the study is to evaluate a new ultraportable ultrasound device, Hepatoscope, for the non-invasive assessment of hepatic steatosis in patients presenting with steatopathy from metabolic origin, by comparing its measurements with current diagnostic modalities, such as MRI PDFF.

The primary objective is to compare ultrasound parameters measurements of ultrasound attenuation, backscattering coefficient and sound speed to the hepatic fat fraction as measured with MRI-PDFF.

The secondary objectives also include the comparison of measurements of liver stiffness as an indicator of liver fibrosis risk in patients at risk of having MASH.

Exploratory objectives have been determined to allow the comparison of said measured parameters to the outcome of histopathological analysis in a subset patient population who would benefit from a liver biopsy.

Eligibility Criteria:
Inclusion Criteria:

* Adult patient below 80 yo
* Patients with MASLD/MASH recruited in interventional trials requiring MRI PDFF +/- MRE per interventional protocol, OR
* Patients with MASLD/MASH recruited in prospective cohorts requiring MRI PDFF +/- MRE per interventional protocol, OR
* Patients referred to MRI-PDFF or MRE.
* Patients who consented in written to participate in the study
* Patients with ongoing social security coverage

Exclusion Criteria:

* Patient in their minority (less than 18 yo) or older than 80 yo,
* Patient with active implants,
* Patient presenting with a wound where the Hepatoscope exman shall be performed (abdominal right upper quadrant)
* Patient with a history of decompensated cirrhosis,
* Patient with a history of hepatocellular carcinoma,
* Adult patient under tutorship, or unable to express informed consent,
* Pregnant or breast-feeding
* Person deprived from their liberty
* Patient hospitalized without providing consent or in case of an emergency
* Patient presenting with another know liver disease
Efficacy, Safety and Tolerability of Telbivudine in HBeAg Positive Chronic Hepatitis B Pregnant Women With Elevated Alanine Aminotransferase Levels

Telbivudine reduces DNA and normalizes alanine aminotransferase levels (ALT) in chronic hepatitis B patients with few adverse effects, but its use during pregnancy has not been explored. In this open-label, prospective study from the second trimester to post-partum week 28. This trial is to study the efficacy, safety and tolerability of Telbivudine in HBeAg Positive Chronic Hepatitis B Pregnant Women with high level of serum HBV DNA and elevated alanine aminotransferase levels.


Eligibility Criteria:
Inclusion Criteria:

* age between 20-40 years
* gestational age between 12-30 weeks
* serum HBsAg and HBeAg positivity
* HBV DNA levels \>6log10 copies/mL
* ALT \>1x ULN (40 IU/mL) and \< 10x ULN.

Exclusion Criteria:

* co-infection with hepatitis A, C, D, E or HIV
* evidence of hepatocellular carcinoma; decompensated liver disease or significant renal, cardiovascular, respiratory or neurological co-morbidity
* concurrent treatment with immune-modulators, cytotoxic drugs, or steroids
* clinical signs of threatened miscarriage in early pregnancy
* evidence of fetal deformity by 3-dimensional ultrasound examination
* the biological father of the child had CHB
Correlation of SpO2/FIO2 Ratio With PaO2/FIO2 Ratio in ARDS Patients in the ICU of H. Adam Malik Hospital

This study to apprehend the relation of SpO2/FiO2 to PaO2/FiO2 in ARDS patients.

Acute Respiratory Distress Syndrome (ARDS) is a life-threatening condition that requires immediate treatment. The measurement of the PaO2/FiO2 (P/F) ratio is the main choice for assessing the severity of ARDS with an invasive method that requires arterial blood gas (ABG) analysis. This study was conducted to determine the relationship between the SpO2/FiO2 ratio and the PaO2/FiO2 ratio in ARDS patients at HAM General Hospital. This observational study used a cross-sectional research method with the total sample of 29 intubated ICU patients diagnosed with ARDS. Patients with congestive heart failure, anemia, and systolic blood pressure \<90 mmHg were excluded from the study. The results of this study showed a positive correlation between the PaO2/FiO2 and SpO2/FiO2 ratios with a correlation coefficient of 0.955 and a p-value of 0.001. There was a relationship between the S/F ratio and the P/F ratio in assessing the severity of ARDS with a p-value of \<0.05. This study shows that the SpO2/FiO2 (S/F) ratio has a good correlation with the PaO2/FiO2 (P/F) ratio in patients with ARDS, so it can be used as a predictor of ARDS and can be beneficial in clinical practice. It should be noted that the SpO2/FiO2 ratio has several factors that can affect its accuracy, so careful assessment is needed.

Eligibility Criteria:
Inclusion Criteria:

* ARDS patient
* intubarted patient

Exclusion Criteria:

* Cardiac congenital disorder
Subclinical Delirium and Clinical Outcome

Delirium has been associated with clinical outcomes in critical care setting. However, its subclinical form has not been investigated. The investigators aimed to establish the association of subclinical delirium with outcome.

Delirium has been associated with clinical outcome in critical care setting. This syndrome has been associated with longer length of stay in ICU and hospital, longer duration of mechanical ventilation and higher mortality rate. however, its subclinical form has not been investigated. The subclinical syndrome is defined by CAM-ICU, in which several features of delirium are fulfilled but the diagnostic criteria are not fulfilled. The investigators aimed to establish the association of subclinical delirium with outcome.

Eligibility Criteria:
Inclusion Criteria:

* patients enter ICU
* GCS \> 10
* RASS \> -2

Exclusion Criteria:

* unable to cooperate
* coma
Enhancing Adjustment to Parental Cancer: Short-term Counselling for Families

A parental cancer diagnosis challenges the family's stability and the parent-child relationship. It may impact the children's well-being, so that about one third of them develop clinically relevant levels of psychological distress. Psycho-oncological family-based counselling programs have been shown to elevate children's and parents' well-being. However, there is still a dearth of familial health services in Switzerland, which has also been recognized by the Swiss National Cancer Program (2011-2017).

This study aims to implement and evaluate a short-term family counselling intervention at the Cancer Center of the University Hospital Basel. The primary objective of the study is the enhancement of adjustment to the parental cancer diagnosis. The study seeks secondary to determine the feasibility of the short-term counselling Intervention.

This study ist designed as a randomized controlled wait-list Intervention study, which aims to implement and evaluate a short-term family counselling intervention at the Cancer Center of the University Hospital Basel. The study will be divided into two stages: Stage 1 serves as the preparatory work phase, where the intervention manual will be developed as well as the implementation strategy into the hospital. In stage 2 the intervention will be evaluated, with an interim analysis to test for feasibility. The primary objective of the study is the enhancement of adjustment (family, parents and children) to the parental cancer diagnosis. The study seeks secondary to determine the feasibility of the short-term counselling intervention in the Swiss medical setting and to identify predictors for families with continuing psychosocial adjustment problems.

Eligibility Criteria:
Inclusion Criteria:

* Informed Consent as documented by signature
* Diagnosis of any kind of cancer, inclusive relapse, within the last year with an expected survival of at least 8 months
* Married, cohabiting or single parent
* At least one child between 1-5 - 18 years
* German speaking

Exclusion Criteria:

* The diagnosis is more than 1 year ago
* Diagnosed patients (parent) not living with their children
* Diagnosed patients without custody of their children
Safety and Clinical Effectiveness of Intravitreal Bevacizumab (Lumiere®) in Patients With Wet Age-related Macular Degeneration (Wet AMD)

The purpose of this clinical trial is to evaluate the safety and clinical effectiveness of intravitreal bevacizumab (Lumiere®) in the single-dose form, for the treatment of patients with wet AMD.

Age-related macular degeneration is the main cause of severe vision loss in patients over 65 years of age. There is solid evidence of the efficacy and safety of bevacizumab in the treatment of wet AMD. However, it has not been registered for such indication yet.

In response to the need for a proper adaptation, Lumiere® has been developed in a single-dose, sterile dosage containing bevacizumab 5 mg/vial in 0.2 mL injectable solution.

This adaptation is intended to assure intravitreal administration avoiding the risk of contamination and potential adverse consequences, such as endophthalmitis and blindness, associated to reutilization or repackaging of bevacizumab vials for oncological use.

Eligibility Criteria:
Inclusion Criteria:

* Patients over 50 years of age diagnosed with wet age-related macular degeneration having indication of antiangiogenic therapy.
* Both genders.
* Subjects able to give informed consent.

Exclusion Criteria:

* Patients with contraindication to receive bevacizumab:

  * Hypersensitivity to the active ingredient or to some of the formula excipients.
  * Hypersensitivity to products derived from CHO cells or to other human recombinant antibodies or humanized antibodies.
* Patients having received intravitreal antiangiogenic therapy prior to wet AMD treatment.
* Patients receiving previous systemic antiangiogenic therapy.
* Wet AMD in the healing period or disciform scar.
* Pregnant, breastfeeding or childbearing-aged women.
* Any person with choroidal neovascularization not associated to wet AMD.
* History of retinal or intraocular surgery in the affected eye in the last three months.
* Vitrectomy in the affected eye.
* Any significant ocular infection, active or suspected, having compromised or able to compromise the eye to be studied.
* Ocular inflammatory disease.
* Myopia exceeding -8 diopters.
* Extensive subfoveal subretinal hemorrhage \> 2 papillary diameter (PD).
* Coexistence of other severe ocular diseases: uncontrolled ocular hypertension, terminal glaucoma, diabetic retinopathy, retinal vein thrombosis, optic atrophy.
* History of stroke or myocardial infarction in the last 6 months.
* Patients with coagulopathies.
* Patients physically or mentally disabled to participate in such visual tests.
Effect of Planned Visual Training on Heart Failure Patients

This study was conducted to evaluate the effects of planned visual education based on the Health Belief Model on the attitudes, beliefs, and symptoms of heart failure patients towards their disease. Planned visual education based on the Health Belief Model has positive effects on the attitudes, beliefs, and symptoms of heart failure patients towards their disease.

This study, which evaluated the effects of planned visual education based on the Health Belief Model on the attitudes, beliefs, and symptoms of patients with heart failure towards their disease, was conducted with 110 heart failure patients. The study was planned as a randomized controlled experimental study conducted on two groups as intervention (n = 55) and control group (n = 55). The study was conducted between September 2021 and March 2022 at Manisa Celal Bayar University (MCBU) Hafsa Sultan Hospital Cardiology Polyclinic. Simple randomization method was used in assigning the sample group to the experimental and control groups. Data were collected using "the Patient Identification Form", "the Health Belief Model Scale - Heart Failure" and "Memorial Symptom Assessment Scale - Heart Failure".

Eligibility Criteria:
Inclusion Criteria:

* Patients aged between 18 and 65,
* Those with no communication problems,
* Those diagnosed with NYHA I-II heart failure,
* Those without cognitive impairment,
* Those who can understand and speak Turkish,
* Those who agree to participate in the study.

Exclusion Criteria:

* Patients who do not agree to participate in the study,
* Patients who want to leave the study,
* Patients with NYHA III-IV heart failure diagnosis,
* Patients diagnosed with cancer,
* Patients with diabetic foot or amputation.